NICE’s Tecfidera Restrictions In MS Leave It Fighting For U.K. Market Share
This article was originally published in The Pink Sheet Daily
Executive Summary
Biogen Idec get nod after providing more data, but restrictions imposed mean Tecfidera is unlikely to leap ahead of a packed field.
You may also be interested in...
Good And Bad News For Genzyme MS Drugs At NICE: Aubagio In; Lemtrada Out For Now
Genzyme had a mixed few days with its MS drugs at NICE, with Aubagio finally succeeding but Lemtrada struggling on the back of a tough benefit/risk profile.
Biogen Idec Undercuts Gilenya With $55,000 Yearly Price For Tecfidera
The company expects dimethyl fumarate’s strong efficacy and favorable safety and tolerability profile to be an advantage against other oral multiple sclerosis drugs.
European HTA Highlights: Discounts Soften NICE Approach But Germany’s IQWiG Shows Its Teeth
It is becoming ever more clear that the overriding factor in NICE’s decision-making process is a desire to see cost-effectiveness, irrespective of the clinical benefit of a drug. But in Germany, companies are challenged by IQWiG’s tightened-up, science-based review system.